Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 250Leukemia 186Lymphoma 137Leukemia, Myeloid, Acute 103Burkitt Lymphoma 90Myelodysplastic Syndromes 79Lymphoma, Non-Hodgkin 65Breast Neoplasms 60Lymphoma, Large B-Cell, Diffuse 59Leukemia, Lymphocytic, Chronic, B-Cell 49Lymphoma, Mantle-Cell 47Hodgkin Disease 47Graft vs Host Disease 46Lymphoma, Follicular 45Leukemia, Myeloid, Accelerated Phase 45Multiple Myeloma 39Leukemia, Myeloid, Chronic-Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Blast Crisis 38Leukemia, Myelomonocytic, Chronic 37Leukemia, Biphenotypic, Acute 35Recurrence 34Lymphoma, Large-Cell, Immunoblastic 33Lymphoma, B-Cell, Marginal Zone 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30Osteosarcoma 29Primary Myelofibrosis 27Neoplasms, Plasma Cell 25Leukemia, Myelogenous, Chronic, BCR-ABL Positive 25

Interventions

Carboplatin 7Trastuzumab 6Docetaxel 5pembrolizumab 4Paclitaxel 4Oxaliplatin 4Fluorouracil 4Cytarabine 4Cyclophosphamide 4Azacitidine 4pertuzumab 3Radiotherapy 3Observation 3Neoadjuvant Therapy 3Epirubicin 3Endoscopy 3Cisplatin 3Chemoradiotherapy 3Capecitabine 3venetoclax 2toripalimab 2sargramostim 2olaparib 2durvalumab 2cc-486 2Tretinoin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Monatide (IMS 3015) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pathologic Complete Response × Methotrexate × Clear all
NCT04314219 2025-03-13

PTCy-PMAT

King Faisal Specialist Hospital & Research Center

Phase 3 Recruiting
264 enrolled
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡